2004 Stock Overview
Huapont Life Sciences Co., Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Huapont Life Sciences Co.,Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥4.64 |
52 Week High | CN¥5.38 |
52 Week Low | CN¥3.78 |
Beta | 0.46 |
1 Month Change | 7.41% |
3 Month Change | 9.95% |
1 Year Change | -12.12% |
3 Year Change | -28.28% |
5 Year Change | -7.75% |
Change since IPO | -52.16% |
Recent News & Updates
Recent updates
Shareholder Returns
2004 | CN Chemicals | CN Market | |
---|---|---|---|
7D | 4.7% | 4.3% | 4.4% |
1Y | -12.1% | -17.4% | -12.6% |
Return vs Industry: 002004 exceeded the CN Chemicals industry which returned -17.4% over the past year.
Return vs Market: 002004 matched the CN Market which returned -12.6% over the past year.
Price Volatility
2004 volatility | |
---|---|
2004 Average Weekly Movement | 4.2% |
Chemicals Industry Average Movement | 8.7% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002004 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002004's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 12,476 | Hai Zhang | www.huapont.com.cn |
Huapont Life Sciences Co., Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and ophthalmology, as well as health management products.
Huapont Life Sciences Co.,Ltd Fundamentals Summary
2004 fundamental statistics | |
---|---|
Market cap | CN¥9.19b |
Earnings (TTM) | CN¥280.54m |
Revenue (TTM) | CN¥11.53b |
32.7x
P/E Ratio0.8x
P/S RatioIs 2004 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2004 income statement (TTM) | |
---|---|
Revenue | CN¥11.53b |
Cost of Revenue | CN¥7.10b |
Gross Profit | CN¥4.44b |
Other Expenses | CN¥4.16b |
Earnings | CN¥280.54m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.14 |
Gross Margin | 38.48% |
Net Profit Margin | 2.43% |
Debt/Equity Ratio | 57.2% |
How did 2004 perform over the long term?
See historical performance and comparison